Skip to content
Clinical Trials – home
Neurocrine Biosciences Inc.
Sponsor

Neurocrine Biosciences Inc.

United States 6027 Edgewood Bend Court, 92130-8235, United States

About the sponsor

Research activity in major depressive disorder includes adjunctive treatment strategies aimed at improving depressive symptoms, maintaining response over time, and evaluating longer-term tolerability in adults with persistent mood symptoms.

  • Major depressive disorder
  • Adjunctive antidepressant therapy
  • Relapse prevention

The sponsor’s work in this area centers on treatment-resistant and recurrent depression, with emphasis on symptom control and sustained clinical benefit.

About Specializations

Neurocrine Biosciences Inc. runs clinical trials in conditions such as Schizophrenia, Major depression, Adrenogenital syndrome, Tardive dyskinesia, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

15 clinical trials

Efficacy, Safety, and Tolerability of NBI-1065890 in Adults with Tardive Dyskinesia

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:Neurocrine Biosciences Inc.

Schizophrenia

Recruiting

A study to evaluate the effectiveness and safety of NBI-1117570 in adults with schizophrenia who require hospital treatment.

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:HTL0022537
  • Sponsor:Neurocrine Biosciences Inc.

Schizophrenia

Recruiting

Long-Term Safety Study of Direclidine in Adults with Schizophrenia

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Direclidine
  • Sponsor:Neurocrine Biosciences Inc.

Schizophrenia

Recruiting

A study testing direclidine compared to placebo in adults with schizophrenia who need hospital care

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Direclidine
  • Sponsor:Neurocrine Biosciences Inc.

Safety and Tolerability Study of NBI-1065845 as Additional Treatment for Adults with Major Depressive Disorder

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE
  • Sponsor:Neurocrine Biosciences Inc.

Study of NBI-1065845 as add-on treatment to prevent depression relapse in adults with Major Depressive Disorder who responded to initial treatment

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE
  • Sponsor:Neurocrine Biosciences Inc.

Evaluating NBI-1065845 as an Additional Treatment for Adults with Major Depressive Disorder Who Are Not Responding Adequately to Current Therapy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE
  • Sponsor:Neurocrine Biosciences Inc.

Assessment of NBI-1065845 as an Additional Treatment for Adults with Major Depressive Disorder

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE
  • Sponsor:Neurocrine Biosciences Inc.

Study on the Effectiveness and Safety of NBI-1065845 for Adults with Major Depressive Disorder

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE
  • Sponsor:Neurocrine Biosciences Inc.

Adrenogenital syndrome

Not yet recruiting

Study of Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia to Reduce Androgen Levels

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Crinecerfont
  • Sponsor:Neurocrine Biosciences Inc.

Schizophrenia

Not recruiting

Study on Valbenazine for Patients with Schizophrenia Not Responding Well to Antipsychotic Treatment

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Valbenazine Ditosylate
  • Sponsor:Neurocrine Biosciences Inc.

Study on the Safety and Effectiveness of Crinecerfont for Children with Classic Congenital Adrenal Hyperplasia

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Crinecerfont
  • Sponsor:Neurocrine Biosciences Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.